REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported ...
--Contract Volumes Continued to Increase, Up 8.0% Year-to-Date-- --Asset Rotation Strategy On Track; Expect To Have Approximately $30 Million of Non-Core Assets Under Contract Or Sold By The End of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback